Upregulated expression of Annexin II is a prognostic marker for patients with gastric cancer

World Journal of Surgical Oncology

Volumn 10, Issue , 2012, Pages

  Zhang, Qi ^a   Ye, Zaiyuan ^a   Yang, Qiong ^a   He, Xujun ^b   Wang, Huiju ^b   Zhao, Zhongsheng ^a  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b Key Laboratory of Gastroenterology of Zhejiang Province   (China)

Author keywords

Annexin II; Gastric Cancer; Prognostic

Indexed keywords

CALCYCLIN; LIPOCORTIN 2; MESSENGER RNA;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; CYTOPLASM; DISEASE SEVERITY; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCINOUS CARCINOMA; PAPILLARY CARCINOMA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNET RING CARCINOMA; STOMACH CARCINOMA; STOMACH MUCOSA; SURVIVAL RATE; TUBULAR ADENOCARCINOMA; TUMOR DIFFERENTIATION; UPREGULATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANNEXIN A2; CARCINOMA, SIGNET RING CELL; CELL CYCLE PROTEINS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GASTRIC MUCOSA; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; S100 PROTEINS; STOMACH NEOPLASMS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84861957116     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-10-103     Document Type: Article

References (38)

1. Sentani K, Oue N, Sakamoto N, Anami K, Naito Y, Aoyagi K, Sasaki H, Yasui W. Upregulation of connexin 30 in intestinal phenotype gastric cancer and its reduction during tumor progression. Pathobiology 2010, 77:241-248. 10.1159/000314966, 21116114.
2. Bi J, Lau SH, Lv ZL, Xie D, Li W, Lai YR, Zhong JM, Wu HQ, Su Q, He YL, Zhan WH, Wen JM, Guan XY. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol 2009, 40:1790-1797. 10.1016/j.humpath.2009.07.005, 19765801.
3. Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC, Xie K. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res 2009, 15:1821-1829. 10.1158/1078-0432.CCR-08-2138, 19223493.
4. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003, 14(Suppl 2):ii31-ii36.
5. Tsugane S, Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer 2007, 10:75-83. 10.1007/s10120-007-0420-0, 17577615.
6. Zhao ZS, Wang YY, Chu YQ, Ye ZY, Tao HQ. SPARC is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 2010, 16:260-268. 10.1158/1078-0432.CCR-09-1247, 20028745.
7. Wang CS, Chao TC, Jan YY, Jeng LB, Hwang TL, Chen MF. Benefits of palliative surgery for far-advanced gastric cancer. Chang Gung Med J 2002, 25:792-802.
8. Seemann J, Weber K, Gerke V. Annexin I targets S100C to early endosomes. FEBS Lett 1997, 413:185-190. 10.1016/S0014-5793(97)00911-3, 9287141.
9. Longerich T, Haller MT, Mogler C, Aulmann S, Lohmann V, Schirmacher P, Brand K. Annexin A2 as a differential diagnostic marker of hepatocellular tumors. Pathol Res Pract 2011, 207:8-14. 10.1016/j.prp.2010.09.007, 20971570.
10. Zhai H, Acharya S, Gravanis I, Mehmood S, Seidman RJ, Shroyer KR, Hajjar KA, Tsirka SE. Annexin A2 promotes glioma cell invasion and tumor progression. J Neurosci 2011, 31:14346-14360. 10.1523/JNEUROSCI.3299-11.2011, 3201988, 21976520.
11. Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 2006, 81:146-156. 10.1016/j.yexmp.2006.03.003, 16643892.
12. Diaz VM, Hurtado M, Thomson TM, Reventós J, Paciucci R. Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut 2004, 53:993-1000. 10.1136/gut.2003.026831, 1774091, 15194650.
13. Bao H, Jiang M, Zhu M, Sheng F, Ruan J, Ruan C. Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol 2009, 90:177-185. 10.1007/s12185-009-0356-8, 19585213.
14. Ranson M, Andronicos NM. Plasminogen binding and cancer: promises and pitfalls. Front Biosci 2003, 8:s294-s304. 10.2741/1044, 12700073.
15. Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J Pathol 2008, 216:131-140. 10.1002/path.2400, 18698663.
16. Kwaan HC. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 1992, 11:291-311. 10.1007/BF01307184, 1423820.
17. Sharma MC, Sharma M. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des 2007, 13:3568-3575. 10.2174/138161207782794167, 18220793.
18. Rezvanpour A, Shaw GS. Unique S100 target protein interactions. Gen Physiol Biophys 2009, 28:F39-F46. 10.4149/gpb_2009_01_39, 20093725.
19. Rehman I, Cross SS, Azzouzi AR, Catto JW, Deloulme JC, Larre S, Champigneuille J, Fromont G, Cussenot O, Hamdy FC. S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors. Br J Cancer 2004, 91:739-744. 2364790, 15280928.
20. Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 2003, 200:39-46. 10.1002/path.1288, 12692839.
21. Lee HS, Lee HK, Kim HS, Yang HK, Kim YI, Kim WH. MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer 2001, 92:1427-1434. 10.1002/1097-0142(20010915)92:6<1427::AID-CNCR1466>3.0.CO;2-L, 11745219.
22. Fukuoka J, Fujii T, Shih JH, Dracheva T, Meerzaman D, Player A, Hong K, Settnek S, Gupta A, Buetow K, Hewitt S, Travis WD, Jen J. Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res 2004, 10:4314-4324. 10.1158/1078-0432.CCR-03-0489, 15240517.
23. Song LB, Liao WT, Mai HQ, Zhang HZ, Zhang L, Li MZ, Hou JH, Fu LW, Huang WL, Zeng YX, Zeng MS. The clinical significance of twist expression in nasopharyngeal carcinoma. Cancer Lett 2006, 242:258-265. 10.1016/j.canlet.2005.11.013, 16412561.
24. Emoto K, Sawada H, Yamada Y, Fujimoto H, Takahama Y, Ueno M, Takayama T, Uchida H, Kamada K, Naito A, Hirao S, Nakajima Y. Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res 2001, 21:1339-1345.
25. Emoto K, Yamada Y, Sawada H, Fujimoto H, Ueno M, Takayama T, Kamada K, Naito A, Hirao S, Nakajima Y. Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 2001, 92:1419-1426. 10.1002/1097-0142(20010915)92:6<1419::AID-CNCR1465>3.0.CO;2-J, 11745218.
26. Zimmermann U, Woenckhaus C, Pietschmann S, Junker H, Maile S, Schultz K, Protzel C, Giebel J. Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome. Virchows Arch 2004, 445:368-374. 10.1007/s00428-004-1103-4, 15338305.
27. Liu JW, Shen JJ, Tanzillo-Swarts A, Bhatia B, Maldonado CM, Person MD, Lau SS, Tang DG. Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene 2003, 22:1475-1485. 10.1038/sj.onc.1206196, 12629510.
28. Qi YJ, He QY, Ma YF, Du YW, Liu GC, Li YJ, Tsao GS, Ngai SM, Chiu JF. Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma. J Cell Biochem 2008, 104:1625-1635. 10.1002/jcb.21727, 18320592.
29. Pena-Alonso E, Rodrigo JP, Parra IC, Pedrero JM, Meana MV, Nieto CS, Fresno MF, Morgan RO, Fernandez MP. Annexin A2 localizes to the basal epithelial layer and is down-regulated in dysplasia and head and neck squamous cell carcinoma. Cancer Lett 2008, 263:89-98. 10.1016/j.canlet.2007.12.029, 18262347.
30. Lokman NA, Ween MP, Oehler MK, Ricciardelli C. The role of annexin A2 in tumorigenesis and cancer progression. Canc Microenviron 2011, 4:199-208.
31. Yeatman TJ, Updyke TV, Kaetzel MA, Dedman JR, Nicolson GL. Expression of annexins on the surfaces of non-metastatic and metastatic human and rodent tumor cells. Clin Exp Metastasis 1993, 11:37-44. 10.1007/BF00880064, 8422704.
32. Yan GR, Ding W, Xu SH, Xu Z, Xiao CL, Yin XF, He QY. Characterization of phosphoproteins in gastric cancer secretome. OMICS 2011, 15:83-90. 10.1089/omi.2010.0056, 20726782.
33. Semov A, Moreno MJ, Onichtchenko A, Abulrob A, Ball M, Ekiel I, Pietrzynski G, Stanimirovic D, Alakhov V. Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation. J Biol Chem 2005, 280:20833-20841. 10.1074/jbc.M412653200, 15788416.
34. Frances R, Tumang JR, Rothstein TL. Extreme skewing of annexin II and S100A6 expression identified by proteomic analysis of peritoneal B-1 cells. Int Immunol 2007, 19:59-65.
35. Nedjadi T, Kitteringham N, Campbell F, Jenkins RE, Park BK, Navarro P, Ashcroft F, Tepikin A, Neoptolemos JP, Costello E. S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility. Br J Cancer 2009, 101:1145-1154. 10.1038/sj.bjc.6605289, 2768105, 19724273.
36. Waisman DM. Annexin II tetramer: structure and function. Mol Cell Biochem 1995, 149-150:301-322.
37. Puisieux A, Ji J, Ozturk M. Annexin II up-regulates cellular levels of p11 protein by a post-translational mechanism. Biochem J 1996, 313:51-55. 1216908, 8546709.
38. Matsumoto T, Murao S, Kito K, Kihana T, Matsuura S, Ueda N. Modulation of S-100 genes response to growth conditions in human epithelial tumor cells. Pathol Int 1997, 47:339-346. 10.1111/j.1440-1827.1997.tb04506.x, 9211520.